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1. Introduction 
Myotonic dystrophy protein kinase (DMPK) is a member of the AGC super family of 
serine/threonine protein kinases (Caenepeel et al., 2004; Manning et al., 2002). The DMPK 
human gene encodes several alternative spliced protein products believed to be involved in 
remodeling of the actin cytoskeleton, mitochondrial dynamics, ion homeostasis and nuclear 
envelope stability. DMPK and its isoforms are mainly expressed in skeletal, heart and 
smooth muscle, and brain, the main targets of myotonic dystrophy type 1 (DM1) (Groenen 
et al., 2000; Ueda et al., 2000). DM1 is the most common form of muscular dystrophy in 
adults with a frequency of 1 in 8,000 individuals worldwide. It is a multisystem dominantly 
inherited disorder characterized by myotonia, progressive muscular weakness and wasting, 
cardiac defects, cataracts and frontal balding, as well as several central nervous system 
(CNS) manifestations (Harper et al., 2002). The disease is caused by the expansion of an 
unstable (CTG)n repeat in the 3’-untranslated region (3’-UTR) of the DMPK gene (Brook et 
al., 1992; Fu et al., 1992; Mahadevan, M. et al., 1992). In healthy population the CTG tract is 
polymorphic with alleles ranging from 5 to 37 in length. Individuals carrying the DM1 
premutation, a tract between 38 and 49 CTG repeats, generally are asymptomatic but are at 
risk of transmitting a pathological expanded mutation. In contrast, a CTG expansion 
between 50 and 4000 CTG repeats results in DM1 disease. Affected families show the 
phenomenon of anticipation; longer expansions correlate with an earlier age of onset and 
more severe course in subsequent generations. Based on their clinical presentation DM1 is 
classified into four subtypes: late onset, classic DM1, childhood onset and congenital DM1 
(CDM) (Harley et al., 1992). An RNA-mediated dominant gain-of-function is currently 
accepted as the pathogenic mechanism to explain features of the DM1. DMPK toxic 
transcripts accumulate as nuclear foci (Davis et al., 1997; Taneja et al., 1995), interfering with 
the activity of RNA-interacting proteins and altering RNA metabolism, notably the splicing 
programme (Ranum & Day, 2004). Although reduced DMPK protein levels in DM1 tissues 
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are well described (Fu et al., 1993; Hofmann-Radvanyi et al., 1993; Krahe et al., 1995; Novelli 
et al., 1993), the specific role of DMPK in the pathogenesis of the disease is not completely 
understood. Studies focused on the biology of this protein had received little attention, as 
protein product of DMPK gene seemed to have no direct role in the disease. Identification of 
novel DMPK targets, and comparative differences of DMPK isoforms have started to emerge 
(Groenen et al., 2000; Kaliman & Llagostera, 2008; Mulders et al., 2011; Oude Ophuis et al., 
2009a; van Herpen et al., 2005). This chapter offers the current knowledge about the 
structure, expression patterns and function of DMPK and its isoforms. A better 
understanding of DMPK biology will enable us to speculate how this protein could be 
involved in the pathophysiology of DM1.  
2. Myotonic Dystrophy Protein Kinase gene 
2.1 Localization and structure of the DMPK gene  
The DMPK human gene is located on the long (q) arm of chromosome 19 at position 13.3 
covering 13 kb in length. The gene is composed of 15 exons coding a full-length protein of 
692 amino acids with a composite domain structure. The DMPK gene is transcribed in the 
telomere-to-centromere orientation, giving rise to a set of primary transcripts that are subject 
to extensive alternative splicing (Figure 1). The (CTG)n repeat lies within the 3’-UTR of the 
gene, in the exon 15 downstream of the translation stop signal, and approximately 500 bp 
upstream of the poly (A) signal (Groenen et al., 2000; Jansen et al., 1992; Mahadevan, M.S. et 
al., 1993).  
Characterization of the promoter region has showed that DMPK gene contains a conserved 
GC box to which the transcription factor Sp1 binds. Four E-box elements within the first 
intron mediate interactions with upstream promoter elements to up-regulate its 
transcription in myoblast (Storbeck et al., 1998).  The (CTG)n repeat tract is located in a gene-
dense region; in fact the expansion overlaps with the promoter region of the downstream 
neighboring SIX5 gene. SIX5 expression is needed for eye development in the fruit fly and 
regulates distal limb muscle development in the mouse (Otten & Tapscott, 1995; Ranum & 
Day, 2004; Wang et al., 1994). In DM1 an anti-sense DMPK transcript is originated from SIX5 
regulatory region. This transcript extends into an insulator element on the 3’UTR of DMPK 
regulating the environmental chromatin structure of the region (Cho et al., 2005).  
2.2 Alternative splicing and DMPK isoforms 
Initial bioinformatic analysis of the DMPK gene, and subsequent expression studies have 
demonstrated that six major DMPK isoforms can arise in both humans and mice as a 
result of extensive alternative splicing. In the full-length polypeptide, four distinct 
domains can be distinguished: a leucine-rich N terminus comprised by 40 amino acid that 
are shared by all DMPK isoforms, a serine/threonine protein kinase domain specified by 
exons 2 to 8, an -helical coiled-coil region encoded by the exons 9 to 12, the VSGGG 
motif and a the C terminus. The presence of VSGGG motif and the nature of the C-
terminus, the most important distinction among DMPK isoforms, are both determined by 
alternative splicing (Groenen et al., 2000; Jansen et al., 1992; Mahadevan, M.S. et al., 1993) 
(Figure 1).  
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Fig. 1. The human DMPK gene and its splicing isoforms. (A) DMPK gene is composed of 15 
exons, represented by rectangles. The (CTG)n expansion mutation over exon 15 is shown. 
Exons that are subject to alternative splicing are also indicated. (B) Schematic representation 
of the protein domain organization of the DMPK isoforms. All isoforms have a leucine-rich 
N-terminus domain (LRD), a serine/threonine protein kinase domain (PDK), a VSGGG 
motif, and an -helical coiled-coil domain. C-terminal tail is specific to each isoform and 
determines their subcellular localization. 
It can be distinguished DMPK isoforms with (A to D isoforms) or without a C-terminal 
extension (DMPK E and F). The alternative splice of the first four nucleotides of exon 14 
produces two different open reading frames (ORFs) encoding proteins with C-terminal tail 1 
or 2. An additional C-terminal with tail 3 is originated by the direct joining of exons 12 and 
15 sequences, due to the splicing of exons 13-14. In this case, an ORF with stop codon at the 
beginning of exon 15 is generated. Altogether, the six distinct isoforms constitutes the 
DMPK profile in different cell types and tissues.  
As predicted, the alternative splicing of DMPK pre-mRNA determines the structure and 
function of DMPK products. For instance, the inclusion of exon 14 generates ~ 70-kDa 
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proteins with a hydrophobic C terminus carrying the tail 1 (isoforms A and B), whereas 
exclusion of the first four nucleotides from this exon results in the production of ~ 70-kDa 
proteins with less hydrophobic C terminus carrying the tail 2 (isoforms C and D). The 
presence of both tail 1 and tail 2 confers to the protein the capacity to anchor into 
membranes of endoplasmic reticulum and mitochondria. In contrast, isoforms with tail 3 as 
C terminus (isoforms E and F) adopt a cytosolic localization (van Herpen et al., 2005; 
Wansink et al., 2003). Interestingly, a tissue-specific expression pattern of DMPK isoforms 
have been showed in brain and smooth, cardiac and skeletal muscle.  
There is a cryptic splice acceptor site in exon 15 of the human DMPK gene that defines the 
inclusion of an additional exon (exon 16). The fusion between exons 14 and 16 results in 
removal of the 5’ part of exon 15, including the (CUG)n repeat, generating the so-called 
DMPK G isoform. This transcript encodes a ~ 69-kDa protein with a unique C-terminal tail 
(tail 4). Because of the absence of the (CUG)n repeat, DMPK G transcripts can freely exit the 
nucleus, which might result in efficient DMPK G expression in DM1 cells (Tiscornia & 
Mahadevan, 2000; Wansink et al., 2003).  
3. The DMPK family of proteins  
DMPK belongs to the AGC super family of related serine/threonine protein kinases 
(Caenepeel et al., 2004; Manning et al., 2002). DMPK shows higher homology with myotonic 
dystrophy kinase-related Cdc42-binding kinases (MRCKs), comprise by MRCK, MRCK 
and MRCKproteins (Figure 2). Regarding to the DMPK kinase domain, there is a 60% of 
sequence identity between DMPK and MRCKs (Leung et al., 1998; Ng et al., 2004). DMPK is 
closely related to the Rho-associated kinases I and II (ROCK1/ROCK2), with 45 and 43% 
identity respectively (Riento & Ridley, 2003), as well as to citron kinase (CRIK), with about 
41% sequence identity (Madaule et al., 1998). DMPK is also related in a lower degree to the 
NDR family (consisting of NDR1, NDR2) and Lat’s proteins (Lat 1 or Lat 2), and more 
distantly, to PKA, PKB (Akt), and PKC, the archetypes of the AGC group (Caenepeel et al., 
2004; Manning et al., 2002). 
3.1 Structural domains of DMPK  
All DMPK family members are composed of the four following domains: an N terminal 
leucine-rich domain, a kinase domain, an -helical coiled-coil region, and the C-terminal 
domain (Groenen et al., 2000; Mahadevan, M.S. et al., 1993) (Figure 1). DMPK and other 
family members have important differences among them, mainly in their size and overall 
protein domain composition. MRCKs, ROCKs and CRIK contain a number of additional 
domains with distinct functions, such as the GTPase binding domain, the pleckstrin 
homology domain (PH), the cysteine-rich domain and the citron homology domain (CNH), 
as shown in the Figure 2 (Riento & Ridley, 2003; Zhao & Manser, 2005). Both DMPK and 
ROCKs are able to form dimmers. Structural studies on DMPK, ROCKs, and MRCK have 
shown that dimerization depends on the regions N- and C-terminal immediately adjacent to 
the kinase domain (Doran et al., 2004; Garcia et al., 2006; Jacobs et al., 2006; Tan et al., 2001). 
DMPK is regulated by activation loop phosphorylation, dimerization and trans-
autophosphorylation (Elkins et al., 2009). Although specific sites have not yet been 
identified, the residues Ser234, Thr240 and Thr403 conserved in DMPK and MRCKs, are 
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probably implicated in DMPK activation (Tan et al., 2001; Wansink et al., 2003). In the 
following sections, the structural domains that comprise DMPK are described in detail. 
3.1.1 Lucine-Rich Domain 
In DMPK, the Leucine-Rich Domain (LRD) encodes a peptide of approximately 70 amino 
acids, in which, almost every fourth amino acid is a leucine. This domain constitutes a 
highly non-polar amino-terminal region that is constant in all DMPK isoforms, and presents 
93% of sequence identity between human and mouse forms. This high degree of interspecies 
conservation suggests a potential role for this domain in DMPK activity (van der Ven et al., 
1993; Waring et al., 1996). A segment of this region conforms the leucine zipper motif, which 
is conserved in all DMPK family members. Although the MRCK and ROCK-II leucine 
zipper motifs mediate the dimerization, or even oligomerization, of GTPase-regulated 
kinases, the DMPK leucine zipper motif seems not to be involved in multimerization (Bush 
et al., 2000; Zhang & Epstein, 2003). Then, the specific role played by the DMPK N-terminal 
leucine-rich domain remains to be revealed. In many cases, protein kinase activity is 
modulated by domains flanking the catalytic domain (Manning et al., 2002). Therefore, it is 
thought that the leucine-rich domain may regulate the DMPK kinase activity, due to its 
proximity to the serine/threonine protein domain. The leucine-rich domain might link 
DMPK to signaling modules, or alternatively may help DMPK to localize to specific 
subcellular compartments (Manning et al., 2002). Further studies are necessary to clarify the 
functional activity of this domain.  
 
Fig. 2. Domain organization of DMPK and five major AGC proteins closely related. All 
proteins present a N-terminal leucine-rich domain (LRD), a protein kinase domain (PKD) 
and a C-terminal domain (C); most of them present also a coiled coil domain. AGC proteins 
have some domains that are distinctive of certain members, such as protein kinase C 
conserved region 1 domain or cysteine-rich domain (C1), pleckstrin homology domain (PH), 
citron homology domain (CNH), P21 Rho binding domain (PBD), Rho effector domain 
(HR1) and ubiquitin-associated domain (UBA).   
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3.1.2 Protein kinase domain 
The catalytic domain between residues 70 and 349 carries out the kinase function. This 
domain transfers the gamma phosphate from nucleoside triphosphate (ATP) to the hydroxyl 
group of serine or threonine residues on the target protein, which results in a 
conformational change that affects protein function. Serine/Threonine protein kinase 
domain has eleven major conserved subdomains, separated by regions of lower 
conservation (Hanks & Hunter, 1995). In the active conformation, the kinase domain folds in 
a structure of two lobes: an N-terminal lobe formed by  sheets with a single  helices (B 
and C helices) and a larger C-terminal lobe containing mainly  helices and the activation 
loop (Huse & Kuriyan, 2002; Krupa et al., 2004; Nolen et al., 2004). Activation loop 
phosphorylation and autophosphorylation of DMPK induce a conformational change that 
stabilizes the kinase domain in an open conformation permissive for substrate binding. The 
ATP binding site is situated in the cleft at the interface of the N-terminal and C-terminal 
lobes. This highly conserved region creates the phosphate-binding loop site (P-loop), that is 
a glycine-rich GXGXG consensus sequence (with  usually being phenylalanine or 
tyrosine) (Hanks & Hunter, 1995). DMPK is also known as a Lys/Arg-directed kinase. An 
invariant lysine (Lys100) in the ATP binding region makes contact with the  and -
phosphates of ATP, promoting in coordination with the P-loop the phosphotransfer from 
ATP (Wansink et al., 2003).  
It is generally accepted that, in the nonphosphorylated state, activation loop folds into the 
active site blocking the binding of ATP and peptide substrate (Adams, 2003; Hanks & 
Hunter, 1995; Johnson et al., 1996). However, mass spectrometry of crystallized recombinant 
DMPK (unphosphorylated) has showed that activation loop occupies a well-ordered 
conformation that does not impede access to the nucleotide or substrates binding sites, 
resembling an active conformation (Elkins et al., 2009). A conserved structure in DMPK and 
ROCK1, the EF/F loop, interact with the activation loop to stabilize this active 
conformation. Also important for catalysis is the position of helix C in close proximity to 
the active site. This helix is highly structured, unlike the structures of several inactive 
kinases, and formation of a bridge between C and 3 (residues Glu119 and Lys100 of 
DMPK) is an indicator of the active kinase conformation. This suggests that DMPK could be 
active without phosphorylation, however there is still the question of what the structural 
impact of phosphorylation at the conserved phosphorylation sites (Ser234, Thr240 and 
Thr403) would be (Elkins et al., 2009).  
3.1.3 The VSGGG Motif 
The VSGGG motif is unique among DMPK-related kinases. As previously mentioned, the 
presence of this pentapeptide is defined by alternative splicing, and is found in A, C, E and 
G DMPK isoforms (Figure 2) (Wansink et al., 2003). It has been shown that VSGGG motif 
modulates DMPK autophosphorylation activity, an event that is usually required to regulate 
activity of many protein kinases (Johnson et al., 1996; van Herpen et al., 2005). The presence 
of Serine 379 in the VSGGG motif has a marked effect on the conformational state of the 
protein but it is not clear whether the presence of the motif increases the kinase activity by 
stabilization of the active conformation, or if the motif makes a turn-motif serine/threonine 
more available for autophosphorylation. Interestingly, it has been showed that DMPK 
isoforms lacking the VSGGG motif (B, D, and F) are also phosphorylated in this region. 
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Adjacent sequences the VSGGG motif may be used as phosphoracceptors (residues Thr375 
or Thr379) or a different conformational regulation is possibly taking place.  
3.1.4 Coiled-coil region 
The coiled-coil domain is a common structural motif, formed by approximately 5% of all 
amino acids in proteins (Wolf et al., 1997), including transcription factors, signaling enzymes 
and motor proteins. Typically, it consists of two to five -helices wrapped around each other 
into a left-handed helix to form a supercoil. Whereas regular-helices go through 3.6 
residues for each complete turn, the distortion imposed upon each helix within a left-
handed coiled-coil in DMPK lowers this value to around 3.5 residues. Thus a heptad repeat 
(seven residues) occurs every two turns of the helix (Landschulz et al., 1988; Lupas, 1996). 
The most commonly observed type of coiled-coil is left-handed, with anywhere from two (in 
designed coiled-coils) to 200 of these repeats in a protein (Burkhard et al., 2001; Kohn et al., 
1997). The heptad repeat is commonly denoted (a-b-c-d-e-f-g)n in one helix, and (a’-b’-c’-d’-
e’-f’-g’)n in the other one (Lupas, 1996; Mason & Arndt, 2004). In this model, a and d are 
typically nonpolar core residues found at the interface of the two helices, whereas e and g 
are solvent exposed polar residues that give specificity between the two helices through 
electrostatic interactions. Interactions between a-a’ and d-d’ helices drive the “hydrophobic 
collapse” and formation of the supercoil, whereas e-g’ and g-e’ ionic interactions determine 
the specificity of the interhelical interaction (Mason & Arndt, 2004). 
In DMPK the coiled-coil domain consist of only ~9 heptad repeats, containing 
approximately 65 amino acids. The DMPK coiled-coil domain is smaller than that of other 
AGC family members (Figure 2). DMPK isoforms could form high-molecular-weight 
complexes, due to homo- and heteromultimerization of up to 10 DMPK molecules (Bush et 
al., 2000; Zhang & Epstein, 2003). This multimerization is mediated by coiled-coil 
interactions, and occurs independently of alternatively spliced protein segments or DMPK 
activity (van Herpen et al., 2005). When a coiled-coil heptad repeat is mutated to glycines, 
the coiled-coil mutants are still capable of autophosphorylation and transphosphorylation, 
but the rates of their kinase activities are significantly lowered. Furthermore, it has been 
shown that the coiled-coil domain is important for the cellular localization of DMPK 
mitochondrial isoforms (van Herpen et al., 2005). In summary, the coiled-coil domain is 
involved in DMPK multimerization, substrate binding, kinase activity and subcellular 
localization. 
3.1.5 C-terminal domain 
The C-terminal domain appears to play an autoinhibitory role as C-terminally truncated 
DMPK activity is increased by 3-fold for MBP and 10-fold for myosin phosphatase target 
subunit (MYPT1). This inhibitory activity is mapped in the residues 550 to 629, which has 
also been implicated in oligomerization (Bush et al., 2000; Wansink et al., 2003).  
Interestingly, alternative splicing affecting the C-terminal domain appears to determine the 
subcellular localization of DMPK isoforms (Groenen et al., 2000). DMPK isoforms with long 
C-terminal domain (DMPK A to D) anchor into membranes of the endoplasmic reticulum or 
mitochondria, whereas isoforms with no C-terminal extension (DMPK E and F) adopt a 
cytosolic localization. 
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The structure of DMPK illustrates that the most varied part of AGC proteins is the long C-
terminal domain, compared with the structure of the closely related ROCKs, MRCKs and 
CRIK. Long C-terminal domain containing 96 and 97 amino acids, are named as tail 1 and 
tail 2, respectively. These tails are characterized by unique structures without homology to 
any other protein and by a single C-terminal hydrophobic stretch. The presence of tail 1 
anchored DMPK A and DMPK B into membranes of the endoplasmic reticulum, whereas 
tail 2 is responsible for DMPK association with the mitochondrial outer membrane (van 
Herpen et al., 2005; Wansink et al., 2003) (Figure 2). Interestingly, presence of the coiled-coil 
region in DMPK C and DMPK D is essential for tail 2 to target isoforms to the mitochondrial 
membrane. Not much is known about the relationship between tail anchor structure and 
membrane specificity, and its avidity for lipid composition. A specific role of the signal 
recognition particle for targeting of similar proteins to the ER has been reported (Abell et al., 
2004), but detailed insight on the mechanism of membrane insertion is currently lacking. 
Data from various studies suggest that shared structural elements in the C terminal reflect 
the only critical features implicated in membrane selectivity. For instance, the fact that 
amino acids in the DMPK A tail are all neutral is consistent with this observation, and may 
determine binding strength. Taking these data together, we can conclude that the strong 
hydrophobic character of the DMPK A isoform constitutes the endoplasmic reticulum 
targeting signal. This is compatible with other studies showing that artificially engineered 
stretches of hydrophobic amino acids of different lengths can be sufficient for endoplasmic 
reticulum targeting (Whitley et al., 1996; Yang et al., 1997). On the contrary, targeting of 
DMPK C to the mitochondrial outer membrane seems to be more elaborate, and additional 
structural information is necessary to make conclusions.  
On the other hand, as showed figure 2, DMPK E and DMPK F isoforms do not contain the 
C-terminal domain. They present only two amino acids long segment, named tail 3, without 
any targeting information (Mulders et al., 2011; Whitley et al., 1996; Yang et al., 1997). 
Although the coiled-coil domain confers by itself no targeting properties, as evidenced from 
the cytosolic localization of DMPK E, the amino acid information in this domain seems to be 
a critical component for the correct association of DMPK C to the mitochondrial outer 
membrane. Finally, the minor human isoform DMPK G, which shows a cytosolic 
localization, has a C-Terminal domain with a function still unknown. Some authors have 
named this C-terminal domain as tail 4 (Wansink et al., 2003). Further studies are necessary 
to known in depth the impact of the C-terminal domain on DMPK isoforms cellular 
localization. 
4. Expression pattern of DMPK 
4.1 Tissue distribution of DMPK 
Expression data based on mRNA analysis (in-situ hybridization, northern blot and RT-PCR) 
have showed a wide expression profile of DMPK in mouse and human tissue samples. 
DMPK mRNA is highly expressed in skeletal, cardiac, and smooth muscle and at lesser 
extent in different brain areas. Others tissues and organs that express DMPK mRNA include 
bone, testis, eye, skin, thymus, lung and liver. In contrast, no expression of DMPK transcript 
is found in ovary, pancreas and kidney (Jansen et al., 1992; O'Cochlain et al., 2004; Sarkar et 
al., 2004). The production of DMPK antibodies by using peptides or recombinant DMPK 
protein as immunogen has made possible the detection of DMPK at protein level (Lam et al., 
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2000; Pham et al., 1998; Ueda et al., 2000). DMPK antibodies recognize protein products 
varying in size from ~42- to 84-kDa, being the smaller proteins (42- to 50-kDa) not real 
products of the DMPK gene (Lam et al., 2000; van der Ven et al., 1993). In general, mRNA 
and DMPK protein expression appear strongly correlated. Highest levels of DMPK gene 
products are found in smooth muscle (Jansen et al., 1992; O'Cochlain et al., 2004; Sarkar et 
al., 2004), heart and skeletal muscle (Groenen et al., 2000; Lam et al., 2000; O'Cochlain et al., 
2004; Sarkar et al., 2004). DMPK at protein level has also been identified in several brain 
regions (van der Ven et al., 1993) both in neurons and glia. Interestingly astrocytes from 
brain cortex show higher DMPK levels compared with neurons (Oude Ophuis et al., 2009a). 
DMPK transcripts and protein products are also detected in fetal eyes, adult retina, corneal 
epithelia and optic nerve (Winchester et al., 1999).  
Expression of DMPK during development has also been explored. DMPK expression is 
significantly increases in skeletal muscle between 9 and 16 weeks of human muscle 
development. The large increase in protein accumulation correlates with the formation of 
second-generation muscle fibers, and the major period of muscle formation. Increase in 
DMPK expression is also observed during in vitro myogenic differentiation (Furling et al., 
2003). In other studies, DMPK protein expression has been revealed in eye, skin and 
intestine chick embryos as well as in heart and skeletal muscle, specifically in postmitotic 
myocytes, where it activates myotubes formation (Harmon et al., 2008). In brain and spinal 
cord of rat, DMPK begins to be expressed after birth and increases gradually to peak at 
postnatal day 21 in many regions. After that and proceeding to the adult stage, DMPK 
expression becomes more restricted to certain cell groups like spinal motor neurons 
(Balasubramanyam et al., 1998). Immunoreactive neurons have been observed in the early 
fetal frontal cortex and cerebellar granule cell layer before 29 weeks of gestation (Endo et al., 
2000).  
Regarding the DMPK isoforms expression pattern, it has been showed that long membrane-
anchored isoforms are expressed in heart, diaphragm and skeletal muscle while short 
cytosolic isoforms are highly expressed in bladder and stomach. Interestingly, both long- 
and short-isoforms are expressed in diverse brain regions (Oude Ophuis et al., 2009a). Other 
reports have demonstrated that the four different ~74-kDa full-length DMPK isoforms are 
present in heart, skeletal muscle and brain, in contrast to the two C-terminally truncated 
~68-kDa isoforms that are restricted to smooth muscle and to a lesser extent at heart 
(Groenen et al., 2000).  
4.2 Differential subcellular localization 
Detailed analyses of the subcellular localization of DMPK isoforms carrying distinct C 
termini have been performed. By applying electron and confocal microscopy and 
immunodetection approaches after overexpressing individual isoforms in several cell types, 
it has been demonstrated that unique sequences arrangement in the C terminus tail of 
DMPK control the specificity of anchoring into intracellular membranes. DMPK E and F 
mouse isoforms carrying a truncated tail present an evident cytosolic localization. In 
contrast, DMPK A, B, C and D mouse isoforms carrying a hydrophobic tail are associated 
specifically with either the endoplasmic reticulum or the mitochondrial outer membrane. In 
agreement with this, the corresponding human DMPK A and C proteins localized to 
mitochondria. Furthermore, the expression of mouse and human DMPK A, but not DMPK C 
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isoforms in mammalian cells caused clustering of ER or mitochondria. That means that 
DMPK has a possible role in organelle distribution and dynamics (van Herpen et al., 2005; 
Wansink et al., 2003). Subcellular localization of the DMPK protein during cardiac myocytes 
differentiation has been analyzed in chicken and mouse cardiac myoblast, and in C2C12 
cells transfected with a vector expressing the DMPK fused to the reporter protein GFP. The 
analysis revealed a shift in the DMPK subcellular localization during myogenesis, from the 
perinuclear region to the cellular membrane, suggesting the possibility that DMPK performs 
different roles during this process (Reddy et al., 1996). Electron microscopy analyses in adult 
rat spinal motor neurons reveal a localization of DMPK in the endoplasmic reticulum and 
dendritic microtubules, suggesting a function in membrane trafficking and secretion within 
neurons associated with cognition, memory, and motor control (Balasubramanyam et al., 
1998). In addition, multiple subcellular localizations have been assigned to DMPK, including 
neuromuscular and myotendinous junctions (Berul et al., 1999; Berul et al., 2000; Shimokawa 
et al., 1997) and terminal cisternae and intercalated discs of skeletal muscle sarcoplasmic 
reticulum (Benders et al., 1997; Pall et al., 2003; Saba et al., 1999). Furthermore, DMPK 
localization to gap junctions of the intercalated discs has been reported in the heart and 
Purkinje fibers (Kaliman et al., 2005; Mounsey et al., 2000b). 
5. DMPK function 
5.1 Transgenic and knockout mice 
In order to elucidate the DMPK function and its possible involvement in DM1 pathogenesis, 
several transgenic and knockout mice had been created. DMPK totally deficient (DMPK-/-) 
mice develop a late-onset and progressive skeletal myopathy showing variation in muscle 
fiber size, increased fiber degeneration and fibrosis with ultra structural changes, and a 50% 
decrease in force generation. Inconsistent and minor changes in head and neck muscle fibers 
in adult mouse are also shown (Jansen et al., 1996; Reddy et al., 1996). In addition, the 
DMPK-/- mouse shows cardiac conductions defects, which include first-, second-, and third-
degree atrioventricular (A–V) block in His-Purkinje regions. This effect demonstrates that 
conduction system is specifically compromised; supporting the idea that loss of DMPK 
plays a significant role in the cardiac DM1 phenotype (Berul et al., 1999; Berul et al., 2000). 
DMPK deficit also cause an enhanced basal contractility of single cardiomyocytes with 
associated increase in intracellular Ca2+, suggesting that DMPK has a modulator role in the 
control of intracellular Ca2+ concentration (Benders et al., 1997; Pall et al., 2003). In addition, 
hypophosphorylation of phospholamban (PLN), a muscle-specific sarcoplasmic reticulum 
Ca2+-ATPase (SERCA2a) inhibitor, causes a deregulation of Ca2+ uptake in sarcoplasmic 
reticulum vesicles of ventricular homogenates from DMPK-/- mice (Kaliman et al., 2005). An 
effect on Na+ current amplitude in DMPK-/- myocytes because of reduced channel number is 
also observed (Mounsey et al., 2000b; Reddy et al., 2002). Supporting this result, multiple 
late re-opening of Na+ channels is observed when DMPK is absent in both cardiac and 
skeletal muscles. This is reflected in a plateau of non-inactivating macroscopic Na+ current 
and prolongation of cardiac action potentials (Lee et al., 2003). Altogether these findings 
suggest the existence of a regulatory DMPK pathway for cardiac contractility, and provide a 
suitable molecular mechanism for DM1 heart pathology. A common feature in DM1 is 
insulin resistance, which is a major factor in the development of type 2 diabetes (Biddinger 
& Kahn, 2006). DMPK-/- mice exhibit impaired insulin signalling in muscle tissues but not in 
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adipocytes and liver. These mice also display metabolic derangements such as abnormal 
glucose tolerance, reduced glucose uptake and impaired insulin-dependent GLUT4 
trafficking in muscle. Altogether, these data indicate that reduced DMPK expression may 
directly influence the onset of insulin resistant in DM1 patients and suggest that DMPK 
could represent a gene of susceptibility to type 2-diabetes (Llagostera et al., 2007). 
A transgenic murine line overexpressing the complete human DMPK gene (Tg26-hDMPK) 
has been generated. In this animal model, skeletal muscle shows myopathy with myotonic 
discharges coupled with deficit in sarcolemmal chloride channels. Deficient exercise 
endurance, fiber degeneration and smooth muscle tone deficit with systemic hypotension 
are also present in the Tg26-hDMPK mouse. Heart from these mice develops 
cardiomyopathic remodeling and propensity for dysrhythmia, characterized by overt 
intracellular calcium overload that promotes nuclear translocation of transcription factors 
responsible for maladaptive gene reprogramming. The cumulative stress induced by 
permanent overexpression of DMPK gene products increases the risk of some distinctive 
muscle traits of DM1 (O'Cochlain et al., 2004). Additional overexpression studies using 
different transgenic lines show enhanced neonatal mortality in addition to hypertrophic 
cardiomyopathy (Jansen et al., 1996). In DM1, membrane inclusions accumulate in lens fiber 
cells producing cataracts. Overexpression of DMPK with enzymatic activity in epithelial 
lens cells led to apoptotic-like blebbing of plasma membrane and reorganization of the actin 
cytoskeleton. This may be relevant to the removal of membrane organelles, a necessary 
process during normal lens differentiation (Jin et al., 2000). 
5.2 DMPK function in muscle and brain tissues 
The function of DMPK protein is not completely understood yet, however, several reports 
have described the participation of this protein in different cellular processes notably in both 
muscle and brain tissues. 
DMPK has been described as an important factor during myogenesis. The differentiation 
process begins with the exit of the proliferating myoblast from the cell cycle and activation 
of the differentiation program throughout the expression of myogenic factors, such as MyoD 
and myogenin. Additionally, morphological changes are needed for myotube formation. 
Overexpression of DMPK in BC3H1 cells (Bush et al., 1996) or its depletion in C2C12 cells 
(Harmon et al., 2008) have demonstrated the role of DMPK as a regulator of myogenin 
expression during muscle differentiation. Overexpression of DMPK in chick cardiac and 
skeletal myocytes, and C2C12 cells provoked rounding cells that are brought to apoptosis, 
which suggest a pro-apoptotic role for DMPK. In addition, depletion of DMPK in C2C12 
cells prevented cell fusion, a necessary step for myotube formation (Harmon et al., 2008). As 
mentioned previously, DMPK knockout transgenic mice have been employed to study the 
function of DMPK. Disruption of normal muscle function both in muscle and heart is 
attributed to altered DMPK expression (Jansen et al., 1996; Reddy et al., 1996). CDM, the 
most severe form of DM1, is associated with several developmental defects that include 
delayed muscle development. Myoblasts from CDM embryos have a reduced capacity to 
differentiate, and interestingly, produce less than 50% of DMPK protein levels, implying a 
specific role for DMPK in embryonic myocyte development (Furling et al., 2001; Furling et 
al., 2003). Overall, these data suggest that DMPK is crucially involved in myogenesis. 
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Ion homeostasis is a determinant mechanism regulated by membrane permeability to 
cations (Na+, Ca2+, K+) or anions (Cl-). Transmembrane ion flux is the predominant factor in 
controlling the excitation–contraction coupling mechanism. Alteration in the function of 
voltage-dependent L-type Ca2+ (the dihidropiridine receptor DHPR) and Na+ channels has 
been shown in DMPK mice models (Benders et al., 1997), which evidences the importance of 
DMPK in the maintenance of this homeostasis. That is consistent with the fact that DHPR is 
a target of DMPK and that its activity is altered in DMPK-/- cells (Benders et al., 1997). 
Reduction in Na+ current amplitude in DMPK-/- mice muscle has also been demonstrated 
(Mounsey et al., 2000b; Reddy et al., 2002). Furthermore, activity and membrane localization 
of chloride channel phospholemman (PLM), which regulates Cl- currents, is also modulated 
by DMPK (Mounsey et al., 2000a). All these data suggest that DMPK is involved in 
regulating the initial events of excitation–contraction coupling in skeletal muscle, and 
controlled then, ion homeostasis. In the other hand, proteins involved indirect or directly 
with the cytoskeleton (MYPT1 and SRF) and nuclear envelope (Lamin A/C) integrity were 
reported as DMPK partners (Harmon et al., 2011; Iyer et al., 2003; Muranyi et al., 2001), 
suggesting the participation of DMPK in these cellular processes.   
One of the most common DM1 alterations, the atrioventricular conduction block, was 
shown to be dependent on DMPK levels in a mechanism not yet understood (Berul et al., 
2000; Saba et al., 1999). In addition, DMPK-/- mice with cardiac contractility deregulation 
exhibit an impaired SERCA2a function. This ATPase is regulated by PLN protein, which is 
phosphorylated by DMPK (Kaliman et al., 2005). Furthermore, cardiac dysfunction, 
hypertrophic cardiomyopathy, propensity for dysrhythmia and enhanced neonatal 
mortality has been reported in the DMPK mice (O'Cochlain et al., 2004). Altogether, these 
findings delineate a feasible molecular mechanism for DM1 heart pathology.  
Participation of DMPK in DM1 brain physiology has also been reported. Mis-localization of 
DMPK occurs in DM1, and even at higher extent in the CDM (Endo et al., 2000). In the CNS an 
involvement of DMPK in important physiological processes has been suggested, including 
membrane trafficking and neuro-secretion. DMPK is expressed in a subpopulation of neurons 
associated with cognition, memory, and motor control. It is localized in the endoplasmic 
reticulum and dendritic microtubules within adult spinal motor neurons (Balasubramanyam 
et al., 1998). DMPK has been also associated with intracellular communication functions, due 
to its synaptic localization in cerebellum, hippocampus, midbrain and medulla (Whiting et al., 
1995). DMPK might contribute to synaptic plasticity and cognitive function via cytoskeletal 
remodeling. Long-term potentiation (LTP) is a use-dependent form of synaptic plasticity that 
contributes to the cellular basis of memory storage and other cognitive functions. Changes in 
the actin cytoskeleton are important for mechanisms underlying LTP including changes in 
synaptic and dendritic spine shapes (Engert & Bonhoeffer, 1999; Fischer et al., 2000; Kim & 
Lisman, 1999). Phosphorylation of myosin phosphatase by DMPK promotes an increase in the 
phosphorylation state of myosin, which supports the assembly and contractility of the actin 
cytoskeleton (Muranyi et al., 2001). Thus, deregulation of DMPK expression could influences 
directly on actin cytoskeleton remodeling (Jin et al., 2000). These data together with abnormal 
LTP measures in a DMPK null mice (Schulz et al., 2003) suggest that DMPK have a key role in 
synaptic plasticity in such a way that DMPK depletion might contribute to the cognitive 
dysfunction associated with CDM, which is characterized by strong motor function and brain 
disability.  
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5.3 DMPK-protein interactions and function 
DMPK protein is a serine/threonine kinase with preference for substrates with an arginine 
residue upstream of the phosphoacceptor site (serine or threonine), followed by a 
hydrophobic residue (usually leucine or valine), and another arginine (Bush et al., 2000). The 
consensus recognition motif on substrates -RxxS/TL/VR- is similar to that of PKC and 
CaMKII. DMPK has the capability to form multimeric complexes among individual 
molecules, as revealed by gel-filtration experiments on cell lysates expressing DMPK A, C, E 
or F isoforms (van Herpen et al., 2006). As remarked previously, coiled-coil domain 
mediates multimerization, which in turn modulates DMPK binding to substrate and 
phosphorylation. Multimerization also influences subcellular targeting properties of 
individual DMPK isoforms (van Herpen et al., 2006; Zhang & Epstein, 2003). On the other 
hand, DMPK targets are involved in important cell functions notably ion homeostasis and 
actin cytoskeleton remodeling (Table 1).  
 
PROTEIN NORMAL FUNCTION DM1 ASSOCIATED 
PHENOTYPE  
REFERENCES 
PLN Ion (Ca2+) homeostasis Cardiac contractility 
alterations 
(Kaliman et al., 
2005) 
PLM Ion (Cl-) homeostasis Myotonia (Mounsey et al., 
2000b) (Mounsey 
et al., 2000a) 
DHPR Ion (Ca2+) homeostasis Deregulation of 
excitation-contraction 
coupling 
(Benders et al., 
1997) (Timchenko, 
L. et al., 1995) 
MYPT Calcium sensitization 
Regulation of the 
cytoskeletal structure   
Calcium 
desensitization 
Cytoskeleton 
rearrangement defects 
(Muranyi et al., 
2001) (Mulders et 
al., 2011)  
SRF Alpha-actin gene 
transcription regulator 
Synaptic plasticity 
abnormalities 
Cataracts  
(Iyer et al., 2003) 
(Schulz et al., 2003) 
(Jin et al., 2000) 
Lamin A/C Nuclear envelope 
integrity  
Muscle wasting (Harmon et al., 
2011) 
CUG-BP Alternative splicing 
regulator  
Splicing alteration (Roberts et al., 
1997) 
ATP synthase 
α and  
Trifunctional 
enzyme  
Mitochondrial proteins  Mitochondrial 
morphology (?)                 
(Forner et al., 2010)  
(Oude Ophuis et 
al., 2009b) 
Table 1. Partners and phosphorylation targets of DMPK implicated in the DM1 phenotype. 
Cardiac contractility dysfunction is an alteration commonly present in DM1 patients and 
DMPK-/- mouse model. Cardiac contraction and relaxation cycle is an important cell process 
regulated by intracellular calcium levels. In cardiac sarcoplasmic reticulum, SERCA2a 
regulates the cytoplasmic levels of Ca2+, and SERCA2a in turn is tightly controlled by the 
sarcoplasmic reticulum membrane protein PLN. Hence, nonhosphorylated PLN inhibits 
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SERCA2a function, whereas phosphorylated PLN reverse such inhibition (Frank et al., 2003; 
MacLennan & Kranias, 2003). It has been reported that PLN is a target of PKA kinase and 
CaMKII. However, Kaliman and co-workers reported that DMPK colocalizes and interacts 
with PLN promoting its phosphorylation. In fact, PLN protein is found under a 
nonphosphorylated state in DMPK-/- mice, where Ca2+ uptake is highly reduced. Disruption 
of the interaction between PLN and DMPK and/or loss of the PLN activity regulatory 
mechanism, due to DMPK downregulation, might explain at least in part the cardiac 
pathology observed in DM1 patients (Kaliman et al., 2005). 
Interestingly, the splicing regulator CUGBP, member of the CELF family, is also a DMPK 
target. CUGBP was described as a CUG-binding protein with high avidity to single-strand 
RNA containing CUG repeats (Ladd et al., 2001).  It has been shown in DM1 patients and 
DMPK knockout mice that phosphorylation and intracellular localization of CUGBP is 
regulated by DMPK. By using immunoprecipitation and kinase activity assays, the 
interaction between CUGBP-DMPK and the subsequent CUGBP phosphorylation were 
demonstrated (Roberts et al., 1997). DMPK phosphorylates CUGBP thereby decreasing its 
nuclear levels, which is consistent with the augment of CUGBP nuclear levels found in 
cultured cells from DM1 patients (Roberts et al., 1997). A plausible interpretation of these 
findings is that DMPK downregulation results in increased levels of the nonphosphorylated 
form of CUGBP, which might cause an increase in the nuclear levels of CUGBP, thereby 
adversely affecting the processing of pre mRNAs. Several reports have described alteration 
in the RNA processing of CUGBP targets genes in DM1 patients, including human cardiac 
troponin T (cTNT) (Philips et al., 1998), transcription factor CCAAT/ enhancer-binding 
protein b (C/EBPb) (Timchenko, N.A. et al., 2001), and  insulin receptor (IR) (Dansithong et 
al., 2005; Savkur et al., 2001). On the other hand, an increase in the steady-state levels of 
CUGBP was revealed in DM1 tissues. This increase is due to an augmentation in the stability 
of the protein, which is mediated by PKC phosphorylation (Kuyumcu-Martinez et al., 2007; 
Timchenko, N.A. et al., 2001). Further studies are necessary to identify specific 
serine/threonine residues on CUGBP that could be phosphorylated in a PKC-or DMPK-
dependent manner. The complete understanding of the two pathways concurring in CUGBP 
phosphorylation would help to better know DM1 pathogenesis. 
PLM is a major membrane substrate for PKA and PKC. In oocytes from Xenopus, PLM 
induces hyperpolarization-activated non-inactivating chloride current (ICl(PLM)) (Moorman et 
al., 1992; Palmer et al., 1991). By in vitro assays Mounsey and co-workers showed that PLM 
is a substrate for DMPK, and that co-expression of both PLM and DMPK reduces ICl(PLM) by 
about half (Mounsey et al., 2000b). Site-directed mutagenesis has demonstrated that reduced 
ICl(PLM) is provoked by decreased PLM expression at the plasma membrane, as a 
consequence of its phosphorylation by DMPK. Furthermore, electrophysiological studies 
have evidenced reduced muscle chloride conductance and membrane depolarization in 
myotonic muscles. On the other hand, mutations in CLCN1 have been reported in the 
myotonia congenital disease condition. As myotonia can be induced by reducing chloride 
conductance, at the plasma membrane, the exploration of PLM phosphorylation state and 
intracellular localization in the mouse model Tg2–hDMPK mouse, which shows reduced 
chloride channel expression (O'Cochlain et al., 2004), would provide insights into the 
development of DM1-asscociated myotonia (Mounsey et al., 2000a). 
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Another target for DMPK is the MYPT1, a component of the myosin phosphatase (MP). MP 
phosphatase activity is inhibited by phosphorylation mediated by Rho-kinase (Hartshorne 
et al., 1998), and such inhibition increases the levels of myosin light chain phosphorylation, 
which in turn leads to Ca2+ sensitization in smooth muscle (Hartshorne et al., 1998). At 
subcellular level, phosphorylation of MYPT1 by DMPK produces cytoskeletal 
rearrangements in non-muscle cells (Muranyi et al., 2001), whereas in-vitro DMPK can 
phosphorylate MYTP1 in the same way that Rho-kinase, suggesting a regulatory role for 
DMPK in myosin function (Muranyi et al., 2001). 
It has been described that deregulation of ion influxes is a key factor for development of the 
DM1 phenotype. Particularly, Ca2+ conductance abnormalities may contribute to 
hyperexcitability of sarcoplasmic membrane in DM1. DHPR, the voltage gating L-type Ca2+ 
channel, shows an altered activity in differentiated myotubes derived from DMPK-/- mice 
(Benders et al., 1997). By applying in-vitro approaches it was demonstrated that DMPK 
phosphorylates the -subunit of DHPR in a serine residue. These data demonstrate that 
DHPR is substrate for DMPK, and suggest that DMPK is involved in the initial events of 
excitation–contraction coupling in skeletal muscle, a mechanism regulated by ion 
homeostasis (Timchenko, L. et al., 1995). DMPK has also been associated with SRF, the 
serum response transcription factor. SRF is a phosphoprotein that regulates skeletal and 
cardiac alpha-actin gene transcription. DMPK phosphorylates the Thr159 residue localized 
in the  1 coil of the DNA-binding domain on a MADS box. By using site-directed 
mutagenesis it has demonstrated that phosphorylation on Thr159 regulates cardiac -actin 
expression at promoter level (Iyer et al., 2003).  
By using high-resolution mass spectrometry, a new group of proteins associated with 
DMPK has been reported (Forner et al., 2010). Authors identified 15 putative partners of 
DMPK grouped as follows: mitochondrial proteins (ATP synthase subunit , ATP synthase 
subunit , trifunctional enzyme subunit ), contractile and myofibrillar proteins (myosin 
heavy chain 7, myosin regulatory light chain 2-skeletal muscle isoform, myosin light chain 
1-skeletal muscle isoform, myosin light chain 3), heat shock proteins (HSP) (-crystallin B 
chain, heat shock protein -1, heat shock protein -6) and other proteins (adenylate kinase 
isoenzyme 1, carbonic anhydrase 3, peroxiredoxin-1, peroxiredoxin-2, similar to 
glyceraldehyde-3-phosphate dehydrogenase). To study in detail some of these DMPK 
interactions, these authors used immunoprecipitation and pull-down assays, and showed 
direct interaction of DMPK with αB-crystallin/HSPB5 and HSP25/HSPB1. These findings 
suggest that DMPK isoforms might modulate some HSPs functions at diverse subcellular 
localizations (i.e. mitochondrial membrane rather than cytoplasm) or under different 
physiological conditions (i.e. oxidative stress opposed to heat production) (Forner et al., 
2010). 
Finally, the participation of DMPK in the integrity of the nuclear envelope (NE) has recently 
been disclosed. NE is an important actor that determines the nuclear structure and regulates 
gene expression.  Key structural elements of NE are the nuclear type-A and type-B lamins. 
Lamin A/C and lamin B1 proteins interact with proteins of the inner nuclear membrane and 
chromatin (Hetzer, 2010). Mutations in inner NE proteins are the genetic cause of Emery-
Dreiffus muscular dystrophy (EDMD) and limb girdle muscular dystrophy 1b (LGMD1B) 
(Roux & Burke, 2007). Thus, NE defects may represent a common mechanism of muscle 
wasting in muscular dystrophies. DMPK localizes to the NE forming a protein complex with 
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lamin A/C, and importantly, overexpression or depletion of DMPK disrupts the nuclear 
envelope localization of both lamin A/C and lamin B1, and causes ultimately nuclear 
fragmentation. Thus, DMPK expression seems to be critical to maintain NE stability. As 
nuclear instability is a common mechanism of muscle wasting in muscular dystrophies 
(Harmon et al., 2011), DMPK misexpression may be an important contributor to skeletal 
muscle wasting in DM1. 
6. DMPK contribution to DM1 phenotype 
6.1 Mechanisms of pathogenesis in DM1 
DM1 is a multisystemic neuromuscular disease characterized by a wide range of clinical 
manifestations, including myotonia, muscle weakness and wasting, cardiac abnormalities, 
cognitive and behavioural alterations, and lens opacities (Harper et al., 2002). Cumulative 
experimental evidence has demonstrated that several DM1 manifestations are the result of 
the nuclear accumulation of CUG repeat-containing transcripts, which interfere with the 
alternative splicing, and gene expression programs (Ranum & Day, 2004). Besides the RNA 
gain-of-function mechanism, additional pathways might contribute to DM1, including 
chromatin rearrangements at the DM1 locus, interference RNA pathways and DMPK 
haploinsufficiency (Figure 3) (Sicot et al., 2011). 
RNA gain-of-function mechanism: Mutated DMPK RNA expression results in decreased 
muscle-blind (MBNL) and increased CUGBP/Elav-like family member 1 (CELF1) activities. 
CUG repeat-containing transcripts form alternative secondary RNA structures that bind to 
and sequester MBNL in nuclear foci altering its normal distribution in the nucleoplasm 
(Jiang et al., 2004; Lin et al., 2006; Mankodi et al., 2005). In addition, CELF1 overexpression 
due to PKC phosphorylation has been described in DM1 cells (Kuyumcu-Martinez et al., 
2007). Deregulation of the splicing transcription factors MBNL and CELF1 disrupts a tightly 
regulated developmental program, leading to altered expression of embryonic splicing 
isoforms in adult tissues (Osborne & Thornton, 2006; Ranum & Day, 2004). Muscle specific 
chloride channel (ClC1), insulin receptor (IR), cardiac troponin T (cTNT), myotubularin 
related protein 1 (MTMR1), microtubule binding protein Tau (MAPT), and NMDA 
glutamate receptor (NR1), are examples of genes affected at the alternative splicing level in 
DM1 (Du et al., 2010; Ranum & Day, 2004).  
Leaching of transcription factors mechanism: It has been reported that mutant DMPK RNA 
interferes with the function of selected transcription factors, depleting them from the active 
chromatin by an RNA leaching mechanism. In fact, altered expression of CLCN1 by leaching 
of Sp-family transcription factors was found in DM1 cells (Ebralidze et al., 2004). It is 
predicted that massive derangement at transcription level, due to leaching of transcript 
factors, is present in DM1 cells.  
Chromatin rearrangements at the DM1 locus, and interference RNA (iRNA) pathways 
mechanism: DMPK gene is transcribed into sense and anti-sense transcripts (Cho et al., 
2005). iRNA pathways might be activated by processing of dsRNA structures that could be 
form due to folding of CUG-containing transcripts into hairpin structures, or due to 
complementary hybridization between complementary sense and anti-sense DMPK 
transcripts. MicroRNA (miRNA) deregulation appears to be an additional mechanism  
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Fig. 3. Mechanisms of pathogenesis in DM1. Toxic CUG-containing transcripts form 
secondary structures and accumulate in the nucleus of DM1 cells, causing the multysistemic 
effects of DM1 throughout RNA gain-of-function mechanism (A), chromatin 
rearrangements at the DM1 locus (B) and DMPK haploinsuffiency (C). See text for details.  
involved in DM1 biogenesis; in fact, the miRNAs pathway was found to be altered in DM1 
skeletal muscle and heart. Interestingly, mi-R1 downregulation is mediated by MBNL1 
depletion in cardiac DM1 tissue, which results in misprocessing of pre-miR-1 (Perbellini et 
al., 2011; Rau et al., 2011). On the other hand, processing of anti-sense transcript might be 
involved in chromatin ultrastructure regulation. It is known that anti-sense DMPK transcript 
extends into an insulator element located between DMPK and SIX5 genes (Cho et al., 2005). 
CTCF-binding sites have been described on each side of the CTG repeat within the DMPK 
gene, restricting the extent of anti-sense RNA expression. Remarkable, the expanded mutant 
allele impairs CTCF binding, and induces spread of heterochromatin and regional CpG 
methylation in CDM cells. It is hypothesised that barrier function of the insulator is missing 
in DM1 due to disruption of CTCF binding, inducing higher DMPK expression in late 
embryogenesis, as a consequence of a high SIX5 enhancer activity, thereby contributing to 
the earlier disease onset in CDM (Sicot et al., 2011). 
6.2 The possible role of DMPK and it isoforms in the pathogenesis of DM1 
Although debated, many studies indicate that CTG expansion causes a decrease in the 
amount of DMPK protein by ~ 50%, with greatly reduced expression from the mutant allele 
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and normal expression from the unaffected allele, a phenomenon known as 
haploinsufficiency (Bhagavati et al., 1996; Furling et al., 2001; Narang et al., 2000). Mice 
model generated to study the effects of DMPK deficiency have revealed an important 
contribution of DMPK to the development of myopathy and cardiac abnormalities (Berul et 
al., 1999; Jansen et al., 1996; Reddy et al., 1996). CDM is an entity of the disease that 
evidences the importance of DMPK expression; because, delayed muscle development and 
reduced capacity for muscle differentiation correlate with a decrease of more than 50% in 
DMPK levels. As stated above, it was recently reported that DMPK is a structural 
component of the nuclear envelope, forming a protein complex with lamin A/C (Harmon et 
al., 2011). In fact, alteration of DMPK expression disrupts the localization of lamins A/C and 
B1, causing nuclear fragmentation. Thus, deficient expression of DMPK in DM1 cells might 
contribute to nuclear instability, a common mechanism of muscle wasting in muscular 
dystrophies. 
In skeletal muscle, the study of DMPK individual isoforms has provides insights into their 
potential contribution to the DM1 phenotype. In DMPK -/- mice myoblasts, exogenous 
expression of the cytosolic DMPK E isoform results in the presence of stress fibers, 
significant changes in myoblast polarity and delay myogenesis progression (Mulders et al., 
2011). It is known that DMPK gene is expressed early in muscle development, but 
alternative splicing down-regulates DMPK E expression during myogenesis (Jansen et al., 
1996; Oude Ophuis et al., 2009a). In contrast, membrane-anchored DMPK splice isoforms 
remain equally abundant between myoblast and myotubes, indicating that expression of 
these isoforms is not differentially regulated during myogenesis. Stress fibers formation 
induced by DMPK E is enhanced by myosin II light chain (MLC2) phosphorylation 
(Mulders et al., 2011). The phosphorylation status of MLC2 is dependent on myosin 
phosphatase (PP1) activity, which is inactivated by phosphorylation of its subunit MYPT1, a 
DMPK substrate. Hence, MCL2 phosphorylation levels are determined by the interplay 
between kinase and phosphatase activities, in which DMPK is involved. Exogenous 
expression of DMPK E causes also changes in cell shape and cell motility, which may be due 
to the abnormally rigid cytoskeletal organization caused by the high content of 
phosphorylated MLC2, which ultimately may impact myogenesis.  
As mentioned previously, brain dysfunction is prominently implicated in DM1. Mental 
manifestations in CDM and adult-onset DM1 include mental retardation, cognitive and 
emotional disturbances, and hypersomnia (de Leon & Cisneros, 2008; Meola & Sansone, 
2007). DMPK transcripts aggregated in foci were observed in brain of postmortem DM1 
tissue (Jiang et al., 2004), suggesting that the RNA-gain of-function mechanism is involved 
in the development of DM1-asociated brain dysfunction. With respect to DMPK, it was 
recently demonstrated that both long and short DMPK isoforms are expressed across many 
brain regions, including brainstem, olfactory bulb, and striatum. In addition, DMPK protein 
was identified in astrocytes and U373 glioblastoma cells (Oude Ophuis et al., 2009a). 
Therefore, involvement of DMPK isoforms in DM1-mediated mental retardation can not be 
ruled out.  
Finally, overexpression of human DMPK A in various cell lines causes abnormal 
mitochondrial morphology, mitochondrial clustering in the perinuclear region, loss of the 
mitochondrial membrane potential, increased autophagy activity, mitochondrial 
fragmentation, and eventually apoptosis (Oude Ophuis et al., 2009b). Interestingly, an 
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abnormal mitochondrial morphology and mitochondrial dysfunction has been described in 
DM1 patients (Siciliano et al., 2001; Ueda et al., 1999). Furthermore, ATP synthase subunit , 
ATP synthase subunit , and trifunctional enzyme subunit , three mitochondrial important 
components, have been described as possible partners of DMPK (Forner et al., 2010). 
Supporting the participation of DMPK isoforms in the DM1 phenotype and mitochondria 
morphology, overexpression of tail-anchored human DMPK isoforms in heart and skeletal 
muscles of Tg26-hDMPK mice causes accumulation of mitochondria in the subsarcolemmal 
space, disorganization of the mitochondrial cristae structure, and importantly, the 
appearance of DM1-like symptoms, including reduced workload tolerance, atrophy, 
cardiomyopathy, and myotonic myopathy (O'Cochlain et al., 2004). Oude Ophuis and cols. 
propose that expression and activity of DMPK isoforms should be tightly controlled, both in 
time and place. Thus, any alteration in the balance of DMPK isoforms expression due to 
changes in mRNA synthesis or pre-mRNA splicing, might contribute to the DM1 
pathophysiology. 
In addition, DMPK deficiency could be involved in specific process of DM1 biogenesis, 
according to its interaction with different protein partners and targets (Table 1). 
7. Conclusion 
DM1 is a neuromuscular multisystemic disease caused by the expansion of the CTG repeats 
in the 3’UTR of the DMPK gene. DMPK primary transcript gives rise to 6 isoforms with 
activity of serine/threonine kinase that differ each other in their capacity to anchor organelle 
membranes. DMPK is expressed mainly in heart, skeletal and smooth muscles, and brain, 
the most compromised tissues in DM1. Current knowledge indicates that clinical 
manifestations of DM1 are not due to a unique molecular mechanism; instead, it appears 
that different mechanisms operate in the development of the disease. In addition to the toxic 
RNA gain-of-function, the best-described mechanism, chromatin rearrangements of the 
DM1 locus, leaching of transcription factors, interference RNA pathways and altered 
expression of DMPK protein should be considered as contributors to DM1 biogenesis. 
Importantly, several partners and targets of DMPK have been reported, suggesting the 
involvement of DMPK in the specific cellular pathways affected in DM1. Although the 
physiological function of DMPK and its isoforms is not yet fully understood, growing body 
of experimental evidence strongly suggests a role for DMPK in DM1 pathophysiology. 
Future studies in different groups of DM1 patients (CDM versus classic DM1), as well as in 
animal and cells models with DMPK deficiency are required to define the participation of 
DMPK in DM1 biogenesis. 
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